Results 271 to 280 of about 277,970 (322)

Pre-clinical efficacy of a candidate Outer Membrane Vesicle gonococcal vaccine in comparison with 4CMenB.

Freixeiro P, Lewis LA, Sánchez-Busó L, Unemo M, Gulati S, Linder A, Corander J, Harrison OB, Dold C, Harris S, Rollier C, Ram S, MacLennan CA.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Genetically modified mouse models in cancer studies

Clinical and Translational Oncology, 2008
Genetically modified animals represent a resource of immense potential for cancer research. Classically, genetic modifications in mice were obtained through selected breeding experiments or treatments with powerful carcinogens capable of inducing random mutagenesis.
Javier, Santos, Pablo, Fernández-Navarro, María, Villa-Morales, Laura, González-Sánchez, José, Fernández-Piqueras   +4 more
openaire   +2 more sources

Modeling RASopathies with Genetically Modified Mouse Models

2016
The RAS/MAPK signaling pathway plays key roles in development, cell survival and proliferation, as well as in cancer pathogenesis. Molecular genetic studies have identified a group of developmental syndromes, the RASopathies, caused by germ line mutations in this pathway.
Isabel, Hernández-Porras, Carmen, Guerra   +1 more
openaire   +2 more sources

Genetically modified mouse models for premature ovarian failure (POF)

Molecular and Cellular Endocrinology, 2010
Premature ovarian failure (POF) is a complex disorder that affects approximately 1% of women. POF is characterized by the depletion of functional ovarian follicles before the age of 40 years, and clinically, patients may present with primary amenorrhea or secondary amenorrhea.
Krishna, Jagarlamudi, Pradeep, Reddy, Deepak, Adhikari, Kui, Liu   +3 more
openaire   +2 more sources

Noonan syndrome: lessons learned from genetically modified mouse models

Expert Review of Endocrinology & Metabolism, 2017
Noonan syndrome is a RASopathy that results from activating mutations in different members of the RAS/MAPK signaling pathway. At least eleven members of this pathway have been found mutated, PTPN11 being the most frequently mutated gene affecting about 50% of the patients, followed by SOS1 (10%), RAF1 (10%) and KRAS (5%). Recently, even more infrequent
Alberto J. Schuhmacher, Isabel Hernández-Porras, Raquel García-Medina, Carmen Guerra   +3 more
openaire   +2 more sources

Genetically modified mouse models for pharmacogenomic research

Nature Reviews Genetics, 2004
It is now evident that differences in the DNA sequence of genes involved with drug action can lead to interindividual differences in effectiveness and adverse reactions to therapeutic drugs. Pharmacogenomics raises the possibility that drug discovery and patient management could move from a 'one drug fits all' approach to one in which therapy is ...
openaire   +2 more sources

New developments in prion disease research using genetically modified mouse models

Cell and Tissue Research, 2023
While much of what we know about the general principles of protein-based information transfer derives from studies of experimentally adapted rodent prions, these laboratory strains are limited in their ability to recapitulate features of human and animal prions and the diseases they produce.
Julianna L. Sun, Glenn C. Telling
openaire   +2 more sources